<code id='D3488413D1'></code><style id='D3488413D1'></style>
    • <acronym id='D3488413D1'></acronym>
      <center id='D3488413D1'><center id='D3488413D1'><tfoot id='D3488413D1'></tfoot></center><abbr id='D3488413D1'><dir id='D3488413D1'><tfoot id='D3488413D1'></tfoot><noframes id='D3488413D1'>

    • <optgroup id='D3488413D1'><strike id='D3488413D1'><sup id='D3488413D1'></sup></strike><code id='D3488413D1'></code></optgroup>
        1. <b id='D3488413D1'><label id='D3488413D1'><select id='D3488413D1'><dt id='D3488413D1'><span id='D3488413D1'></span></dt></select></label></b><u id='D3488413D1'></u>
          <i id='D3488413D1'><strike id='D3488413D1'><tt id='D3488413D1'><pre id='D3488413D1'></pre></tt></strike></i>

          leisure time

          leisure time

          author:focus    Page View:91939
          NASDAQ
          Spencer Platt/Getty Images

          Emergent BioSolutions, the manufacturing company that fell into hot water in 2021 due to a contamination issue involving millions of doses of Covid vaccines, is pivoting its business and cutting hundreds of jobs, including a C-suite role.

          The company announced Tuesday that it will cut 400 jobs and eliminate the role of chief operating officer as part of a shift away from its contract manufacturing services business. The current chief operating officer, Adam Havey, will leave the company on Sept. 30.

          advertisement

          Instead, Emergent will focus on producing Narcan nasal spray and other products. The overdose reversal medicine became available as an over-the-counter medicine earlier this year.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more
          Readout Newsletter: Merck, Vertex, and Viking updates
          Readout Newsletter: Merck, Vertex, and Viking updates

          MelEvans/APNewbiotechnewsletterlaunchingthisThursday. Don’tmissout.Hello,everyone.Damianherewithaloo

          read more
          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more

          Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

          AllenG.Breed/APNewbiotechnewsletterlaunchingthisThursday.Don’tmissout.Heythere.Today,wediscusstheimp